Compare Bristol-Myers Squibb Co (BMY) vs Kingsoft Cloud Holdings Limited (KC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Kingsoft Cloud Holdings Limited — how do they compare? Bristol-Myers Squibb Co trades at $63.57 (market cap $129.94B), while Kingsoft Cloud Holdings Limited trades at $11.65 (market cap $3.53B). The key difference: Bristol-Myers Squibb Co is far larger — about 36.8× Kingsoft Cloud Holdings Limited's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Kingsoft Cloud Holdings Limited pays none. Which is the better fit depends on your goals.
| BMY | KC | |
|---|---|---|
Market Cap | $129.94B | $3.53B |
Sector | Health | Technology |
52-Week High | $65.89 | $18.21 |
52-Week Low | $42.60 | $8.58 |
Enterprise Value | $163.92B | $3.84B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Kingsoft Cloud (KC) trades at $11.66, down 2.55% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported revenue growth of 37% year-over-year in Q1 2026, driven by AI cloud services, but net income remains negative at -$936 million for 2025. Analyst consensus is strongly bullish with 70% buy ratings, citing AI-driven expansion and undervaluation relative to peers.
The outlook is positive due to AI revenue acceleration and analyst optimism, but risks include persistent losses, high capital expenditure, and competitive pressures in China's cloud market. Investors should weigh growth potential against profitability challenges ahead of Q2 2026 earnings on August 19, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Kingsoft Cloud Holdings Limited
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →
